How ENBREL Works

Although the exact cause of rheumatoid arthritis (RA) is unknown, elevated levels of TNF are found in the involved tissues and fluids of patients with RA. Elevated levels of TNF are also found in the tissues and fluids of patients with psoriatic arthritis and ankylosing spondylitis (AS).1

ENBREL is a moderate to severe rheumatoid arthritis treatment and fully human soluble tumor necrosis factor (TNF) receptor. ENBREL is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.1

ENBREL was designed to bind specifically to TNF and block its interaction with cell surface TNF receptors, thereby modulating the biological responses induced or regulated by TNF, including the inflammatory responses that play an important part in RA, psoriatic arthritis, AS, and juvenile idiopathic arthritis.1,2

ENBREL binds to TNF, limiting the amount of active TNF.1,3,4

Rheumatoid Arthritis Treatment
Tumor necrosis factor (TNF; yellow) attaches to TNF "receptors" (purple) on immune cells, which trigger a cellular response.
Rheumatoid Arthritis Treatment
This response can be modulated by soluble TNF receptors that are released from cells.
Rheumatoid Arthritis Treatment
ENBREL (orange/purple) works like the body's soluble TNF receptors, capturing TNF before it attaches to these immune cells.
 
Supportive data
Moderate to Severe Rheumatoid Arthritis

In medical studies, ENBREL was shown to be clinically effective in about 2 out of 3 adults with moderate to severe RA at 3 months. ENBREL has been shown to begin working in as few as 2 weeks, and most patients who benefit will do so within 3 months. In another medical study, 55% of patients who were evaluated 5 years after beginning ENBREL therapy had no further progression of joint damage.

Psoriatic Arthritis

In a medical study, ENBREL was shown to be effective in about 50% of psoriatic arthritis patients at 6 months. Clinical responses were apparent at the time of the first visit (4 weeks) and were maintained through 6 months of therapy.

Important Safety Considerations

Lean on
ENBREL Support for personalized patient assistance

Here's how we can help

The experience of ENBREL

Evaluated in RA clinical studies over the past 20 years*

See our timeline history
*Initial clinical research in RA patients began in 1993.
 
 
Close
You are leaving Enbrel.com/RheumPro
Please know that Amgen does not endorse and are not responsible for the content included on the site you are about to enter. Click the "Continue" button to proceed.

To return to ENBREL.com, click "Cancel" or close this window.

Privacy Policy  Terms of Use
This site is intended for US Audiences only.
©2013 Amgen, Inc., Thousand Oaks, CA 91320
Close
E-mail this page to a colleague
Please correct the fields marked in red
Send
This content is for US health care professionals only. Amgen will not use your e-mail address or your colleague's e-mail address for any other purpose. To learn more about our use of your information and your rights, please consult our Privacy Policy.
Close

Send another e-mail
Return to enbrel.com/RheumPro

Close
We're sorry.

This content is not available at this time.

Close
Notice

The following information is intended for use only by residents of the United States. Countries outside of the United States may have regulatory requirements or medical practices that are different than those in the United States and may require reference to different or additional information. Therefore, this information may not be appropriate outside of the United States.

If you are a resident of the United States or one of its territories, or a health care professional practicing your profession in the United States or one of its territories, please click below.

If you are a resident of a country other than the United States, please visit the Amgen website to find information about our offices around the globe.
Close
Phil Mickelson: A PsA patient's perspective
Close
Disease activity vs. structural progression in RA
Close
Treating Moderately Active RA
Close
Rapid, Sustained Efficacy of ENBREL
Close
Improving Outcomes in Psoriatic Arthritis
Close
A look back at 15 years